- Home
- GMM vs DTIL Comparison
GMM vs DTIL Comparison
Compare GMM & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GMM | DTIL |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 123.0M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GMM | DTIL |
|---|---|---|
| Price | $1.34 | $4.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 15.4K | ★ 197.0K |
| Earning Date | 08-18-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | $0.73 | ★ N/A |
| Revenue Growth | ★ 41.74 | N/A |
| 52 Week Low | $1.23 | $3.61 |
| 52 Week High | $4.97 | $8.82 |
Technical Indicators
Market Signals| Indicator | GMM | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 34.65 | 42.80 |
| Support Level | $1.28 | $4.61 |
| Resistance Level | $1.41 | $5.20 |
| Average True Range (ATR) | 0.09 | 0.34 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 30.78 | 41.08 |
Price Performance
Historical ComparisonAbout GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.